Patients With Rheumatoid Arthritis Who Had Poor Response To Other Drugs Could Have Better Results With Golimumab

An article published Online First and in this week’s edition of reports information about Golimumab, a new tumour necrosis factor-α (TNF-α) inhibitor. It reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-α inhibitor. This drug might be a good alternative for patients who have inadequate responses to one or two other TNF-α inhibitors. Over three million people in Europe and about 1.

More: continued here

Filed under: Arthritis on June 29th, 2009